Novo Nordisk A/S
corporate_fare Company Profile
Novo Nordisk A/S (NYSE:NVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NVO at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Novo Nordisk Initiates DKK 3.8 Billion Share Repurchase Program for 2026
- Novo Nordisk Annual Report Details $4.2B Q1 2026 Revenue Boost, DKK 15B Share Buyback Amidst 2026 Outlook Decline
- Novo Nordisk Reports Mixed 2025 Results, Projects 2026 Adjusted Sales Decline Amid Headwinds
- Novo Nordisk Issues Mixed 2026 Outlook with Adjusted Sales/Profit Decline Amidst Pricing Pressures
- CagriSema Phase 3 Trial Shows Superior HbA1c Reduction and Weight Loss in Type 2 Diabetes
Financial Snapshot
Insider Transactions
NVO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.